Speakers


  • speaker

    William Kuziel Director, External Scientific Affairs Daiichi Sankyo William received his PhD in Immunology in 1988 from the University of Texas Southwestern Graduate School of Biomedical Sciences. In the External Scientific Affairs group within Daiichi Sankyo, he focuses on in licensing biologics and related technologies.

  • speaker

    Pam Trail VP Regeneron Pharmaceuticals Pamela Trail is Vice President Oncology at Regeneron. Prior to this she served as the VP of Oncology at MedImmune and held positions at Seattle Genetics, Bayer, and Bristol-Myers Squibb. Dr. Trail has over 20 years of experience in developing antibody drug conjugates as cancer therapeutics. She received her PhD from the University of Connecticut.

  • speaker

    Neil Bander Professor Weill/Cornell Medical College Neil Bander is the Bernard and Josephine Chaus Professor of Urologic Oncology at Weill/Cornell Medical College and Memorial Sloan-Kettering Cancer Center. Dr. Bander is a physician-scientist whose clinical and laboratory research efforts focus on the discovery and development of antibody-based imaging and therapeutic agents for urologic cancers. Read more...

  • speaker

    Sanela Bilic Senior Fellow, Clinical Pharmacology Novartis

  • speaker

    Paul Davis CEO Quanta BioDesign Paul’s vision for providing a full range of specifically designed single molecule reagents for therapeutic and diagnostic applications can be seen in the expanding range of products offered by Quanta. Paul has his Ph.D. in chemistry, and has almost 30 years of R&D experience. Before starting Quanta, he held key technical/management positions at Molecular Probes Life Technologies and Pierce Thermo Fisher.

  • speaker

    Jonathan Drachman Senior VP Seattle Genetics Jonathan Drachman joined Seattle Genetics in November 2004. He oversees the company's research, preclinical and early clinical development activities. Prior to joining Seattle Genetics, Dr. Drachman was Associate Professor in the Hematology Division, Department of Medicine at the University of Washington in Seattle, where he remains a Clinical Associate Professor of Medicine. Dr. Drachman received a B.A. in Biochemistry from Harvard University and an M.D. from Harvard Medical School.

  • speaker

    Trevor Hallam CSO Sutro Biopharma Dr. Hallam brings more than 25 years of experience in drug discovery and development to Sutro. Most recently, he was executive vice president of research & development and executive officer at Palatin Technologies where he was responsible for discovery and clinical development and led the development of several INDs for drug candidates in a variety of therapeutic areas. Read more...

  • speaker

    William Olson Principal Scientist Progenics Bill joined Progenics in 1994. He has also served as a Research Scientist at Johnson & Johnson, and as a Development Scientist at MicroGeneSys. He received his PhD from MIT.

  • speaker

    Paul Parren Senior VP & Scientific Director Genmab Dr. Parren has been working in the field of recombinant antibodies for 25 years. He holds a PhD in molecular immunology from the University of Amsterdam (1992). Dr. Parren serves in the position of Senior Vice President and Scientific Director and heads the Genmab Utrecht site.

  • speaker

    George Pettit Regents Professor of Chemistry Arizona State University George R. Pettit, Ph.D. attended Washington State University where he completed (1952) the BS degree in Chemistry. He proceeded to Wayne State University and earned the MS degree in heterocyclic chemistry in 1954 and the Ph.D. in steroid chemistry in 1956. Both were under the direction of Professor Carl Djerassi, who discovered the first practical oral contraceptive. Dr. Pettit then finished a one-year postdoctoral in a pharmaceutical unit of Proctor & Gamble Co. Read more...

  • speaker

    Mark Wright Site Lead, High Potency ADC Unit Piramal Healthcare Mark Wright is the Development Manger at Piramal Healthcare for Research and Development projects in the antibody drug conjugate field. He has been working with ADC projects at Piramal Healthcare for 6 years and has been working with protein - toxin conjugates for 9 years.

  • speaker

    George Badescu Head of Bioconjugation and Bioanalysis PolyTherics Dr George Badescu is Head of Bioconjugation and Bioanalysis at PolyTherics and has been leading PolyTherics’ ADC Program since its inception. Since joining PolyTherics in 2008, George has managed multiple bioconjugation projects as well as the Technology Transfer of three projects which have been out-licensed. George is co-inventor on several PolyTherics patents in the field of bioconjugation and ADCs. Prior to this, George has worked on lead identification by viral display technologies, antibody engineering and characterisation of antibody-hapten interactions. He has invented a novel biosensor technology that exploits the specificity of antibody recognition for continuous in vivo monitoring of small-molecule analytes. George received his PhD from the University of Warwick.

  • speaker

    Kinney Horn Associate Director, Business Development Genentech Kinney Horn is an Associate Director in Business Development at Genentech. Mr. Horn is involved in licensing transactions for novel therapeutics, technologies and intellectual property. Mr. Horn joined Genentech in 2003 in the R&D finance group. Read more...

  • speaker

    Juhani Saarinen CEO Glykos Juhani Saarinen is the CEO of Glykos ltd, a Finland based biotech working with some of the world’s largest pharmaceutical companies on glycomics related projects. Mr. Saarinen is an inventor in over 25 patent families ranging from ADC technologies, cancer and cancer stem cells to engineering of therapeutic proteins and stem cell glycomics.

  • speaker

    Dennis Benjamin Vice President, Experimental Therapeutics Seattle Genetics

  • speaker

    John Lambert EVP & CSO ImmunoGen John Lambert joined ImmunoGen in 1987. Prior to this, he was an Assistant Professor at Harvard Medical School. Dr. Lambert holds a Ph.D. in Biochemistry from the University of Cambridge.

  • speaker

    Jay Harper Scientist II, Oncology Research MedImmune Jay Harper received his Ph.D. in Cell & Developmental Biology from Harvard University in 2000 and conducted postdoctoral research on the initiation of the angiogenic switch with Marsha Moses, Ph.D. in the Vascular Biology Department at Boston Children’s Hospital. After joining Genzyme in 2006, he helped build their ADC capabilities and then, since 2011, has used that experience to progress the ADC pipeline of MedImmune, the worldwide biologics unit of AstraZeneca.

  • speaker

    Laurent Ducry Group Leader, Bioconjugates R&D Lonza

  • speaker

    Pavel Strop Associate Research Fellow Pfizer Pavel Strop received his Ph.D. in 2002 from Caltech, where he worked on structural elucidation of mechanosensitive ion channels. Afterwards, he moved to Stanford where he studied proteins involved in synaptic transmission. In 2008, he joined Rinat-Pfizer's protein engineering department where he develops and applies novel technologies including bispecifics and antibody drug conjugates.

  • speaker

    Henry Lowman CSO Cytomx Therapeutics Henry Lowman joined CytomX in September 2010 and currently serves as chief scientific officer. Most recently, Dr. Lowman was the director of protein sciences at NGM Biopharmaceuticals. Read more...

  • speaker

    Damon Meyer Principal Scientist Seattle Genetics Damon Meyer received his Bachelor’s degree in Chemistry from Pomona College, and his Ph.D. from the University of California at Davis. Working first at Hybritech, Inc. then NeoRx Corp., he developed antibody-enzyme conjugates and antibody-streptavidin conjugates for the delivery of oncolytics and radionuclides to tumors. Joining Seattle Genetics in 2000, Dr. Meyer worked on antibody-drug conjugates for preclinical studies, studied the affinity of auristatins for tubulin, and the relationship between affinity and cytotoxicity. Dr. Meyer helped develop the commercial conjugation manufacturing process for Adcetris and the Phase I clinical conjugation process for an anti-CD33-pyrrolobenzodiazepine dimer engineered-cysteine ADC.

  • speaker

    David Jackson Principal Scientist & ADC Program Leader Igenica David Jackson is a Principal scientist and ADC program leader at Igenica with nearly 20 years of pharmaceutical and biotechnology experience in small molecule and ADC drug discovery and preclinical development. He previously led multiple projects at Genentech from early discovery through IND and was the ADC team leader (2003-2006) when T-DM1 was selected for clinical development. He is co-author of 34 peer-reviewed publications and co-inventor on more than a dozen patents.

  • speaker

    Paul Davis Owner Quanta Biodesign Paul Davis’ vision for providing a full range of specifically designed single molecule reagents for therapeutic and diagnostic applications can be seen in the expanding range of products offered by Quanta. Paul has his Ph.D. in chemistry, and has almost 30 years of R&D experience. Before starting Quanta, he held key technical/management positions at Molecular Probes Life Technologies and Pierce Thermo Fisher.

  • speaker

    David Rabuka President, Chief Scientific Officer and Founder Redwood Bioscience Dr. Rabuka received a Ph.D. in Chemistry at the University of California, Berkeley as a Chevron Fellow in the lab of Professor Carolyn Bertozzi. His research included developing and applying Redwood’s platform technology to cell surface modification. Read more...

  • speaker

    Dhaval Shah Senior Scientist Pfizer

  • speaker

    Dimiter Dimitrov Head, Protein Interaction Group, Senior Investigator NCI

  • speaker

    Florence Lhospice Director, Pharmaceutical Operations Innate Pharma Florence Lhospice, pharm D joined Innate Pharma in 2002. She completed pharmacy study at University of Joseph Fourier (France) and University of Montreal. She started working on small molecule targeting T Lymphocyte in the CMC field. Read more...

  • speaker

    Melissa Schutten Scientist-Pathologist Genentech Melissa Schutten is currently a Pathologist-Scientist in the Safety Assessment Pathology group at Genentech. In this capacity, she supports primarily oncology programs in late stage research through development and is involved with the preclinical safety assessment of a variety of novel antibody-drug conjugate therapeutic candidates. Read more...

  • speaker

    Maximillian Yeh Key Accounts Director Evonik In his role as Key Accounts Director, Max Yeh supports the growing Evonik Health Care Business line by specializing in HPAPIs, drug conjugates and injectable formulation services. Prior to joining Evonik, Max worked at Monsanto, Solutia, Cambrex, and Waterstone Pharmaceuticals in various roles in Process Technology, Process Control, Sales, Business Development and Strategy. Read more...

  • speaker

    Tim Lowinger CSO Mersana Therapeutics Tim Lowinger joined Mersana in 2008. He has over eighteen years of experience in the pharmaceutical/biotech industry and brings a wealth of international experience to his role in leading our Research team. Read more...

  • speaker

    Ed Reilly Associate Director II, Cancer Therapeutic Abs, GPRD, Cancer Discovery AbbVie Ed Reilly is an immunologist who trained as a Postdoctoral Fellow and Visiting Scientist at the MIT Center for Cancer Research in the laboratory of Herman Eisen. He presently serves as a Project Director in the Oncology Discovery Group within AbbVie where he leads several late stage Discovery ADC programs.

  • speaker

    Frank Koehn Research Fellow, Natural Products/World Wide Medicinal Chemistry Pfizer Frank Koehn obtained his Ph.D. degree in 1982 from the University of Wisconsin– Madison. Following postdoctoral work at the University of Pennsylvania, he joined the Harbor Branch Oceanographic Institution in Fort Pierce, Florida. In 1994 he moved to Lederle Laboratories which subsequently became Wyeth, and then in 2009 became Pfizer. At Pfizer his laboratory is focused on the application of microbial natural products as ADC payloads.

  • speaker

    Jan Pinkas Director ImmunoGen Jan Pinkas joined ImmunoGen, Inc. in 2008 and is currently Director of Pharmacology. Dr. Pinkas leads a research team charged with utilizing animal model systems to understand features of ImmunoGen’s antibody-maytansinoid conjugates that impact tolerability, pharmacokinetics, metabolism and anti-tumor activity. Read more...

  • speaker

    Yilma Adem Formulation Scientist Genentech Yilma Adem has been working in Genentech since 2007. He works in Early Stage Pharmaceutical Development Department as a formulation scientist and currently, leads an ADC formulation development project. He has a B.sc degree in Biology/Zoology from University of Eastern Africa Baraton and a Master’s in Medical Product Development Management from San Jose State University.

  • speaker

    Dave Colcher Deputy Director, Division of Radioimmunotherapy City of Hope David Colcher joined the City of Hope in 2002 in the Department of Cancer Immunotherapeutics & Tumor Immunology as the Director of the Research Radiopharmacy, Director of the Small Animal Imaging Core and Professor in the Beckman Research Institute. Read more...

  • speaker

    John Flygare Senior Scientist Genentech John Flygare is the project leader for the research stage antibody-drug-conjugate program at Genentech (South San Francisco, CA USA). He received his PhD from Northwestern University and did postdoctoral training at Stanford, both in synthetic chemistry.

  • speaker

    Nitya Ray Senior VP, Manufacturing Progenics Pharmaceuticals Nitya Ray, Ph.D. joined Progenics Pharmaceuticals in 2001 as Senior Director, Manufacturing. He was promoted to Vice President in 2004 and Sr. Vice President, Manufacturing in 2008. Read more...

  • speaker

    Kevin Pinney Professor of Chemistry, Department of Chemistry & Biochemistry Baylor University Dr. Kevin G. Pinney joined the faculty in The Department of Chemistry and Biochemistry at Baylor University in 1993 having completed his Ph.D. at The University of Illinois followed by a NIH Postdoctoral Research Fellowship at The University of South Carolina. Dr. Pinney is currently a Professor of Chemistry at Baylor University and is also a member of The Institute of Biomedical Studies. Read more...

  • speaker

    Omar Kabbarah Scientist, Oncology Biomarker Development Genentech

  • speaker

    Allan Ader Vice President & Principal Toxicologist SafeBridge Consultants Inc Allan Ader has over 25 years experience in the pharmaceutical and chemical industry including working for Syntex, Inc. in Palo Alto, CA and Olin Corporation, New Haven, CT. He received a Ph.D. in Industrial Health (Toxicology) from the University of Michigan and an M.S. in Industrial Hygiene from Temple University. He is a Diplomate of the American Board of Toxicology.

  • speaker

    Godfrey Amphlett Vice President, Process & Analytical Development ImmunoGen Godfrey Amphlett received his Bachelors degree in Natural Sciences from Trinity College, Cambridge, England and his PhD in Biochemistry from the University of Birmingham. Since 2001 he has been at ImmunoGen, Inc. in Cambridge and, more recently, Waltham, Massachusetts, where he has led the Process and Analytical Development department. In this capacity he has been responsible for process, analytical and formulation development for ImmunoGen’s proprietary platform of Antibody Maytansinoid Conjugates.

  • speaker

    Karyn O’Neil CSO Centyrex, Johnson & Johnson Karyn O’Neil is the Chief Scientific Officer of Centyrex, a J&J Venture focused on the development of alternative scaffold technologies for therapeutic proteins. Read more...

  • speaker

    April Xu Senior Principle Scientist & Group Leader Pfizer April Xu is a Senior Principle Scientist and group leader at Pfizer. Her current work is focused on analytical method development and process/product characterization for antibody drug conjugates. She has also worked extensively in analytical development and characterization for vaccines and therapeutical proteins at Pfizer/Wyeth and Regeneron prior to her current position.

  • speaker

    Petter Veiby Global Head of Biotherapeutics, Oncology DDU Millennium

  • speaker

    David Goldenberg Chairman & CSO Immunomedics David Goldenberg, ScD, MD, is the founder of Immunomedics, Inc., where he is Chairman and Chief Scientific Officer. Read more...

  • speaker

    Greg Landes Biotechnology Consultant DNA Bridges

  • speaker

    Maria Elena Guadagno Business Director BSP Pharmaceuticals

  • speaker

    Lisa Hardwick Research Scientist Baxter Biopharma Solutions

  • speaker

    Cynthia Wooge Global Strategic Marketing SAFC

  • speaker

    Melanie Smitt, M.D. Senior Medical Director Genentech Melanie Smitt, M.D. is currently a Senior Medical Director at Genentech and Clinical Science Lead for trastuzumab emtansine, having joined the program in 2010. Previously, she was an Associate Professor of Radiation Oncology at Stanford University through 2007, and also worked at Amgen prior to joining Genentech.

  • speaker

    Jiang He Associate Professor University of Virginia

  • speaker

    Elizabeth Homans VP, Regulatory Strategic Services Genentech

  • speaker

    Michele Dougherty Product Quality Reviewer, Division of Monoclonal Antibodies FDA Michele Dougherty has been a Product Quality Reviewer in the Division of Monoclonal Antibodies, US Food and Drug Administration since 2008. Read more...

  • speaker

    Matthew Hutchinson Senior Engineer Genentech Matt Hutchinson received a PhD in Chemical Engineering from the University of Cambridge. He has been at Genentech since 2006, where he has worked on developing purification and conjugation processes for multiple ADCs. In addition, Matt is a member of the Technical Development Team for Kadcyla (T-DM1).

  • speaker

    David Miao Founder & CSO Concortis Biosystems David Miao, Ph.D., is Chief Scientific Officer and Cofounder of Concortis Biosystems Corp. His responsibilities in this role encompass managing Concortis internal R&D and global collaborations, including strategic planning, project management, budgeting, and resource allocation. Read more...

  • speaker

    Iwan Bertholjotti Head of ADC Program Management Lonza Visp

  • speaker

    Conrad Roten Head of R&D for HPAPI/Cytotoxics Lonza Visp

  • speaker

    Alison Keene Head of Global Regulatory Affairs Lonza Pharma

  • speaker

    Dan Pereira Senior Director, Discovery Research Agensys Daniel Pereira is Senior Director of the Discovery Research Department at Agensys Inc., an affiliate of Astellas Pharma Inc. Read more...

  • speaker

    James Garrison Head, Business Development & Commercial Strategy Progenics Pharmaceuticals

  • speaker

    Wolfgang Noe Ph.D. VP, Technical Operations Agensys During Wolf Noe’s 28-year career in the Biotech industry, he played a leading role in cell culture process development, cell culture based manufacturing, and manufacturing alliances within various organizations. Read more...

  • speaker

    Floris van Delft CSO SynAffix

  • speaker

    Klaus Kaiser Global Drug Discovery, Global Biological Development Bayer Klaus Kaiser received his Ph.D. in Biochemistry at the Laboratory for Molecular Biology / Gene Center of Ludwig-Maximilians-University Munich. Read more...

  • speaker

    Denis Patrick Senior Director, Head, External R&D Innovation, Oncology Research Unit Pfizer Denis Patrick, Ph.D., joined Pfizer in August of 2010 as Senior Director and Head of External R&D Innovation (ERDI) for the Oncology Research Unit (ORU). Read more...

  • speaker

    William C. Fanslow Scientific Executive Director, Therapeutics Innovation Unit Amgen